Roche To Meet With Generic Firms On Tamiflu Rights After Intervention From Senators
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche agrees to meet with Teva, Mylan, Ranbaxy and Barr to discuss granting manufacturing rights for Tamiflu in order to meet growing global demand for the avian flu antiviral.
You may also be interested in...
Roche Agrees To Grant Tamiflu Manufacturing Rights To 15 Companies
Teva and Mylan are among the firms that have agreements with Roche to manufacture generic versions of the flu therapy.
Roche Agrees To Grant Tamiflu Manufacturing Rights To 15 Companies
Teva and Mylan are among the firms that have agreements with Roche to manufacture generic versions of the flu therapy.
Ranbaxy Estimates Production Capacity For Generic Tamiflu
The generics firm said it will be capable of producing the Roche antiviral’s active pharmaceutical ingredient at a rate of 22 tons per annum.